TrialCancer research and treatment2021

A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1.

Cheol-Kyu Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.